Financial Reports Latest Updates Industry Maps Economic Calendar

Viking Therapeutics, Inc. (VKTX) Annual Reports

Q: Where can I read Viking Therapeutics, Inc. (VKTX) annual reports?

Every year on this page links straight to the full text on SEC EDGAR. US annual reports are web pages (HTML) rather than PDFs, so you can read and search them in the browser. 3 filings are currently indexed.

Q: What is the difference between a 10-K and a 20-F?

A 10-K is the annual report of a US domestic issuer; a 20-F is filed by foreign private issuers (Taiwanese companies with US ADRs, such as TSMC, file 20-F). A 40-F applies to Canadian issuers under the MJDS.

Viking Therapeutics, Inc. is listed on Nasdaq, classified by the SEC under Pharmaceutical Preparations (SIC 2834). This page indexes 3 annual reports, each linking to the full text on the SEC's EDGAR system.

Company profile

Exchange： Nasdaq
Fiscal year end： 12/31
SEC CIK： 1607678 →

Website：Official site ↗

Financial Highlights

FY2026 Q2 (quarterly, ended 2026-06-30)
	Current	Prior year	YoY
Revenue	$0	$0	—
Operating income	$-132.6M	$-74.6M	-77.8%
Net income	$-128.0M	$-65.6M	-95.3%
EPS (diluted)	$-1.10	$-0.58	-89.7%

Source: SEC EDGAR (XBRL company facts)

Financial history

Revenue & profit

Quarterly · In mn (USD)

Revenue 0 mn Net income -128 mn

Show table：Income statement

Item	2014Q1	2014Q2	2014Q3	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Revenue	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Operating income	-0.21	-21.8	-1.15	-0.35	-0.46	-2.63	-4.29	-4.62	-3.27	-3.58	-3.26	-3.74	-4.97	-4.98	-4.69	-4.43	-4.80	-6.92	-7.39	-7.04	-6.81	-9.57	-7.44	-8.87	-10.9	-10.6	-9.84	-11.3	-14.2	-15.5	-13.4	-12.5	-16.2	-17.6	-16.2	-20.3	-20.5	-23.7	-27.3	-29.3	-34.1	-34.0	-36.6	-46.2	-55.5	-74.6	-98.6	-165	-164	-133
Net income	-0.23	-22.8	-0.26	1.39	-5.71	-7.87	-4.74	-5.09	-3.59	-3.69	-3.81	-3.64	-5.22	-5.17	-6.10	-4.08	-3.55	-6.67	-6.60	-5.24	-4.92	-7.67	-5.73	-7.45	-9.69	-9.57	-9.29	-10.9	-14.0	-15.4	-13.2	-12.4	-16.1	-17.4	-15.8	-19.6	-19.5	-19.2	-22.5	-24.6	-27.4	-22.3	-24.9	-35.4	-45.6	-65.6	-90.8	-158	-158	-128

Balance sheet

Quarterly · In mn (USD)

Total assets 522 mn Total liabilities 114 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Show table：Balance sheet

Item	2014Q1	2014Q2	2014Q3	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Current assets	—	—	—	0.77	0.36	22.3	18.9	15.2	12.2	18.3	15.6	14.0	14.7	14.3	11.5	21.9	78.7	144	307	302	299	294	289	284	276	271	263	256	250	238	224	211	193	180	165	167	149	399	381	367	966	946	937	907	866	827	739	716	608	518
Total assets	—	—	—	3.04	2.77	22.3	19.0	15.4	12.8	18.6	16.3	14.5	15.2	14.3	11.8	22.1	79.0	144	307	302	300	294	290	284	277	271	264	257	250	238	224	211	195	182	167	169	151	401	383	368	968	947	938	908	867	828	739	716	608	522
Current liabilities	—	—	—	22.5	27.7	4.88	5.72	1.98	1.92	5.74	6.08	6.48	3.38	7.73	9.61	8.66	6.34	4.11	4.74	4.55	4.92	5.63	6.19	6.78	8.54	9.05	9.72	12.1	12.9	12.9	11.3	8.78	11.3	14.9	14.1	21.9	15.7	13.5	13.4	19.1	32.8	25.1	25.7	27.4	19.6	32.0	26.1	76.7	106	110
Total liabilities	—	—	—	25.2	30.6	4.88	5.74	6.71	6.99	5.76	6.10	6.49	7.61	7.73	9.61	8.66	6.34	4.11	4.74	4.56	5.51	6.14	6.63	7.14	8.82	9.25	9.83	12.2	12.9	12.9	11.3	8.78	12.8	16.3	15.4	23.2	16.8	14.6	14.4	20.1	33.6	25.9	26.4	28.0	20.1	32.4	26.4	76.7	106	114
Equity	—	—	—	-22.1	-27.8	17.4	13.3	8.72	5.77	12.8	10.2	8.04	7.55	6.59	2.23	13.5	72.6	140	302	298	295	288	283	277	268	262	254	244	237	225	213	202	182	165	151	145	134	386	368	348	934	921	911	880	847	795	713	639	502	408

Cash flow

Quarterly · In mn (USD)

Operating -125 mn Investing 109 mn Financing 23.6 mn

Positive = cash in, negative = cash out.

Show table：Cash flow statement

Item	2014Q1	2014Q2	2014Q3	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Operating	-0.1	-0.44	-0.61	-0.44	-0.41	-1.62	-3.40	-3.30	-2.73	-3.23	-2.65	-2.46	-3.28	-4.20	-3.33	-3.95	-5.30	-5.27	-5.50	-2.68	-3.15	-6.46	-3.40	-11.7	-4.30	-6.67	-5.32	-5.49	-10.9	-13.4	-10.9	-12.3	-10.5	-13.4	-13.5	-10.9	-24.6	-11.4	-19.7	-17.6	-6.13	-28.5	-22.0	-31.2	-52.3	-47.1	-94.0	-85.3	-114	-125
Investing	—	—	—	—	—	-12.2	-3.25	1.96	5.97	-4.83	0.44	1.45	2.04	-0.76	1.39	-4.40	-29.6	-66.6	-27.1	-142	-7.61	11.0	15.2	-11.1	11.2	9.78	-9.63	30.3	-6.63	3.56	13.6	27.4	1.62	19.0	26.9	7.26	2.20	-204	-12.5	35.7	-460	-126	25.9	6.58	63.3	42.5	160	75.6	54.2	109
Financing	0	1.25	0.51	0.4	-0.02	23.0	-0.7	-0.03	-0.06	9.26	0.11	1.04	2.52	4.00	1.11	14.8	62.3	70.2	167	0.34	0.33	0.26	0.07	0.23	0.03	0.42	0.04	0.46	5.19	1.90	-0.26	0.05	-5.01	-1.59	0.01	10.8	4.18	267	-0.07	0.19	606	2.91	2.52	1.00	0.35	0.51	0.48	75.1	12.1	23.6
Cash at period end	0.08	0.89	0.79	0.76	0.33	9.50	2.14	0.77	3.96	5.16	3.05	3.08	4.36	3.39	2.57	8.99	36.4	34.6	170	24.8	14.3	19.1	30.9	8.38	15.3	18.8	3.87	29.1	16.8	8.83	11.3	26.4	12.4	16.2	29.4	36.6	18.4	69.5	37.2	55.5	196	43.9	50.4	26.7	37.9	33.9	100	166	118	126

Returns & leverage

Quarterly · %

ROE -88.8% ROA -79.2% Debt ratio 21.8%

ROE / ROA = trailing four-quarter net income ÷ average equity / total assets (annual mode: the year’s net income ÷ average of opening and closing). Not computed when the denominator is zero or negative.

Show table：Returns & leverage

Item	2014Q1	2014Q2	2014Q3	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
ROE	—	—	—	—	—	-71.6%	-127.5%	—	—	-113.4%	-137.7%	-175.7%	-245.8%	-184.2%	-323.6%	-191.3%	-47.2%	-27.8%	-13.7%	-14.2%	-12.8%	-11.4%	-8.1%	-9.0%	-10.8%	-11.8%	-13.4%	-15.2%	-17.3%	-20.4%	-22.9%	-24.6%	-27.2%	-30.3%	-33.8%	-39.7%	-45.7%	-26.9%	-31.1%	-34.8%	-17.6%	-14.8%	-15.5%	-17.9%	-14.4%	-20.0%	-29.2%	-47.3%	-70.0%	-88.8%
ROA	—	—	—	-719.1%	-988.2%	-55.9%	-89.0%	-253.3%	-274.1%	-83.8%	-91.6%	-98.3%	-117.3%	-108.6%	-143.0%	-112.3%	-40.2%	-25.7%	-13.1%	-13.6%	-12.4%	-11.1%	-7.9%	-8.8%	-10.6%	-11.5%	-13.0%	-14.6%	-16.6%	-19.5%	-22.0%	-23.5%	-25.6%	-28.2%	-31.5%	-36.3%	-41.8%	-25.4%	-29.4%	-32.0%	-16.8%	-14.4%	-15.0%	-17.2%	-14.0%	-19.3%	-28.3%	-44.3%	-64.0%	-79.2%
Debt ratio	—	—	—	827.2%	1105.3%	21.9%	30.2%	43.5%	54.8%	31.1%	37.4%	44.7%	50.2%	54.0%	81.2%	39.1%	8.0%	2.8%	1.6%	1.5%	1.8%	2.1%	2.3%	2.5%	3.2%	3.4%	3.7%	4.7%	5.2%	5.4%	5.1%	4.2%	6.5%	9.0%	9.2%	13.8%	11.2%	3.6%	3.8%	5.5%	3.5%	2.7%	2.8%	3.1%	2.3%	3.9%	3.6%	10.7%	17.5%	21.8%

EPS

Quarterly · US$

EPS US$-1.10

Show table：EPS

Item	2014Q1	2014Q2	2014Q3	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
EPS（US$）	—	—	—	—	—	—	—	—	—	—	—	—	-0.23	—	—	—	-0.10	—	—	—	-0.07	—	—	—	—	—	—	—	—	-0.20	-0.17	-0.16	-0.21	-0.23	-0.21	-0.26	-0.25	-0.19	-0.23	-0.25	-0.26	-0.20	-0.22	-0.32	-0.41	-0.58	-0.81	-1.39	-1.37	-1.10

Revenue & profit

Year-to-date · In mn (USD)

Revenue 0 mn Net income -286 mn

Year-to-date = summed from the first quarter of the fiscal year; balance-sheet items are period-end balances.

Balance sheet

Year-to-date · In mn (USD)

Total assets 522 mn Total liabilities 114 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Cash flow

Year-to-date · In mn (USD)

Operating -239 mn Investing 164 mn Financing 35.7 mn

Positive = cash in, negative = cash out.

Returns & leverage

Year-to-date · %

ROE -88.8% ROA -79.2% Debt ratio 21.8%

EPS

Year-to-date · US$

EPS US$-2.47

Revenue & profit

Annual · In mn (USD)

Revenue 0 mn Net income -360 mn

Annual = sum of four quarters of a complete fiscal year (incomplete years are omitted); balance-sheet items are year-end balances.

Show table：Income statement

Item	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Revenue	0	0	0	0	0	0	0	0	0	0	0	0
Operating income	-23.5	-12.0	-13.8	-19.1	-26.2	-32.7	-42.7	-55.7	-70.3	-101	-151	-393
Net income	-21.9	-23.4	-14.7	-20.6	-22.1	-25.8	-39.5	-55.0	-68.9	-85.9	-110	-360

Balance sheet

Annual · In mn (USD)

Total assets 716 mn Total liabilities 76.7 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Show table：Balance sheet

Item	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Current assets	0.77	15.2	14.0	21.9	302	284	256	211	167	367	907	716
Total assets	3.04	15.4	14.5	22.1	302	284	257	211	169	368	908	716
Current liabilities	22.5	1.98	6.48	8.66	4.55	6.78	12.1	8.78	21.9	19.1	27.4	76.7
Total liabilities	25.2	6.71	6.49	8.66	4.56	7.14	12.2	8.78	23.2	20.1	28.0	76.7
Equity	-22.1	8.72	8.04	13.5	298	277	244	202	145	348	880	639

Cash flow

Annual · In mn (USD)

Operating -279 mn Investing 341 mn Financing 76.4 mn

Positive = cash in, negative = cash out.

Show table：Cash flow statement

Item	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Operating	-1.59	-8.73	-11.1	-14.8	-18.8	-24.8	-21.8	-47.6	-48.4	-73.4	-87.8	-279
Investing	—	—	3.03	-1.73	-266	7.46	41.6	38.0	54.8	-179	-553	341
Financing	2.17	22.2	10.3	22.4	300	0.89	0.95	6.88	4.16	271	612	76.4
Cash at period end	0.76	0.77	3.08	8.99	24.8	8.38	29.1	26.4	36.6	55.5	26.7	166

Returns & leverage

Annual · %

ROE -47.3% ROA -44.3% Debt ratio 10.7%

Show table：Returns & leverage

Item	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
ROE	—	—	-175.7%	-191.3%	-14.2%	-9.0%	-15.2%	-24.6%	-39.7%	-34.8%	-17.9%	-47.3%
ROA	-719.1%	-253.3%	-98.3%	-112.3%	-13.6%	-8.8%	-14.6%	-23.5%	-36.3%	-32.0%	-17.2%	-44.3%
Debt ratio	827.2%	43.5%	44.7%	39.1%	1.5%	2.5%	4.7%	4.2%	13.8%	5.5%	3.1%	10.7%

EPS

Annual · US$

EPS US$-3.19

Show table：EPS

Item	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
EPS（US$）	—	—	—	—	—	—	—	—	-0.91	-0.92	-1.00	-3.19

Source: SEC EDGAR (XBRL company facts)

Annual reports by year

	10-K
2025	Open full text →
2024	Open full text →
2023	Open full text →

10-K: annual report of a US domestic issuer. Filings are the original documents hosted on SEC EDGAR — this site neither mirrors nor edits them.

FAQ

Where can I read Viking Therapeutics, Inc. (VKTX) annual reports?

Every year in the table above links straight to the full text on SEC EDGAR. US annual reports are web pages (HTML) rather than PDFs, so you can read and search them in the browser without downloading anything. 3 filings are currently indexed.

What is the difference between a 10-K and a 20-F?

A 10-K is the annual report of a US domestic issuer, with sections fixed by law: Item 1 Business, Item 1A Risk Factors, Item 7 Management's Discussion and Analysis. A 20-F is filed by foreign private issuers — Taiwanese companies with US ADRs, such as TSMC, file 20-F rather than 10-K. A 40-F applies to Canadian issuers under the MJDS.

Are earnings call materials available here?

No. Earnings calls are not SEC filings, so US pages on this site cover annual reports only. Taiwan has a mandatory investor-conference disclosure regime, and those materials are indexed under Annual Reports.

Source: US Securities and Exchange Commission (SEC) EDGAR. This site indexes public filings and links to them; it hosts no copies, offers no investment advice, and makes no warranty as to timeliness or completeness.
Back to US annual reports, or see the supply-chain maps.